Welcome to our dedicated page for Teleflex Incorporated news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex Incorporated stock.
Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical devices for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.
The company’s diverse product portfolio spans across several key segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and others. These segments collectively cover a wide range of medical needs, from complex surgical interventions to everyday critical care requirements.
Teleflex’s vascular access segment, contributing 24% to 2023 sales, includes innovative solutions for secure and reliable bloodstream access. The interventional segment, accounting for 17%, focuses on cutting-edge devices for minimally invasive procedures. Anesthesia and surgical segments, with 13% and 14% of sales respectively, offer advanced tools and technologies to improve patient outcomes during surgeries.
The company’s interventional urology segment, noted for its UroLift™ System, addresses benign prostatic hyperplasia (BPH) with minimally invasive solutions that preserve patient quality of life. Original-equipment manufacturing and other segments contribute 11% and 10% of sales respectively, underscoring Teleflex’s broad manufacturing capabilities and diverse product offerings.
Teleflex's geographic exposure is primarily in the United States, which generates 60% of its revenue, with international markets contributing the remainder. The company’s global reach and diverse product lines highlight its significant impact on the healthcare industry worldwide.
In recent years, Teleflex has achieved notable success with a 6.5% constant currency revenue growth in 2023, driven by the expansion of its geographic presence and the launch of innovative new products. The company has strategically acquired Palette Life Sciences AB, enhancing its portfolio and operational efficiencies.
Teleflex remains committed to its mission of providing solutions that improve outcomes and enhance safety for patients and healthcare providers. By leveraging purpose-driven innovation, Teleflex continues to address unmet clinical needs and advance healthcare technologies.
For more information about Teleflex and its comprehensive product offerings, please visit teleflex.com.
Teleflex Incorporated has launched the Arrow® ErgoPack® Complete CVC System, marking a significant update in more than a decade. This system is designed after extensive research with vascular access professionals and includes features such as the Arrow GlideWheel™ Advancer for improved control and a kink-resistant nitinol guidewire. With a focus on reducing CLABSI, the system complies with major health guidelines. Teleflex's Arrowg+ard Blue Plus® CVC is the only full-spectrum antimicrobial catheter addressing key pathogens linked to CLABSI, which causes up to 28,000 deaths annually in the U.S.
Teleflex Incorporated (NYSE: TFX) is set to release its third-quarter 2020 financial results before the market opens on October 29, 2020. An investor conference call will follow at 8:00 a.m. ET. Interested parties can access the live audio webcast on the company’s website. The replay of the call will be available from November 29, 2020, until November 3, 2020. Teleflex is dedicated to improving health through medical technologies across various fields, including vascular access and surgical care.
Teleflex Incorporated (NYSE: TFX) has received 510(k) clearance from the U.S. FDA to extend the indications for use of the Arrow® EZ-IO® Intraosseous Vascular Access System. This device can now be utilized for up to 48 hours when traditional intravenous access is challenging. The expansion is particularly vital for patients requiring long-term access during emergencies.
According to Corporate Vice President Michelle Fox, this advancement aims to enhance patient care during times of resource constraints.
NeoTract, a subsidiary of Teleflex (NYSE: TFX), has recognized Dr. Erik Alexander from Arizona Urology Specialists as a UroLift® Center of Excellence for his expertise in treating Benign Prostatic Hyperplasia (BPH) with the UroLift System. This FDA-cleared, minimally invasive procedure offers an effective treatment for BPH symptoms without surgical side effects. Over 40 million men in the U.S. suffer from BPH, and the UroLift System has treated over 100,000 patients, providing durable symptom relief and improved quality of life.
Liam Kelly, Chairman, President and CEO of Teleflex (NYSE: TFX), will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 2:00 p.m. ET. A live audio webcast and slide presentation will be available on Teleflex's investor website. Teleflex is a global provider of medical technologies focused on improving health and quality of life through innovative solutions in various medical fields, including vascular access and anesthesia.
Teleflex Incorporated's CEO, Liam Kelly, will present at the Wells Fargo 2020 Virtual Healthcare Conference on September 9, 2020, at 12:40 p.m. (ET). A live webcast of his presentation will be accessible on the company's investor section of the website. Teleflex is a global medical technology provider focused on improving healthcare through innovative solutions across various medical fields such as vascular access, cardiology, and respiratory care.
Teleflex (NYSE: TFX) released its 2nd annual Global JOIN Impact Report, detailing progress made in 2019 on corporate social responsibility initiatives focusing on environmental sustainability and community engagement. The report highlights efforts in promoting pollination awareness under the theme ‘Planting with Purpose’. CEO Liam Kelly praised employee dedication to their mission of improving health and quality of life globally. The report is accessible via the company's website.
NeoTract, a subsidiary of Teleflex, has designated Dr. Robert Waguespack as a UroLift® Center of Excellence for his expertise in treating Benign Prostatic Hyperplasia (BPH). The UroLift System offers a minimally invasive solution for BPH, indicated by major urological associations and supported by clinical data showing rapid symptom relief. This procedure is gaining traction as an alternative to traditional medication and surgery, with over 100,000 men treated in the U.S. alone. The UroLift's FDA clearance and positive patient outcomes highlight its role in improving urological health for millions of men.
Teleflex (NYSE: TFX) has declared a quarterly cash dividend of $0.34 per share. This dividend will be paid on September 15, 2020 to shareholders recorded by the close of business on August 14, 2020. As a global provider of medical technologies, Teleflex focuses on innovations that enhance patient care. The company’s diverse portfolio includes solutions in areas like vascular access and anesthesia, reflecting its commitment to meeting clinical needs. For more details, visit teleflex.com.
FAQ
What is the current stock price of Teleflex Incorporated (TFX)?
What is the market cap of Teleflex Incorporated (TFX)?
What does Teleflex Incorporated do?
Where is Teleflex Incorporated headquartered?
How many people does Teleflex employ?
What are the main segments of Teleflex's business?
What percentage of Teleflex’s revenue comes from the United States?
What recent acquisitions has Teleflex made?
What is the UroLift™ System?
What was Teleflex's revenue growth in 2023?
How can one access Teleflex's investor conference calls?
What is the mission of Teleflex Incorporated?
